Clinical trialNCT05024097RecruitingPhase 2Interventional

A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.

SponsorWeill Medical College of Cornell UniversityEnrollment43Rectal Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Enrolled patients will receive upfront (week 1) short-course radiotherapy to gross pelvic disease (25Gy in 5fx) in combination with AB928 (150 mg orally, once daily as part of a continuous dose regimen). This will be followed by consolidation chemotherapy (weeks 3-20) with mFOLFOX x9 cycles in combination with AB928 and AB122.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Encouse Golden, M.D., Ph.D.
Weill Medical College of Cornell University
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Brooklyn Methodist Hospital - Newyork Presbyterian
New York, New York, United States
Hani Ashamalla, M.D.
Recruiting
New York Presbyterian Hospital - Queens
New York, New York, United States
Andrew Brandmaier, M.D.
Recruiting
Weill Cornell Medical College
New York, New York, United States
Encouse Golden, M.D., Ph.D.
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

EtrumadenantFOLFOX regimenZimberelimab

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Mar 2022
Primary completion: 31 Dec 2026
Completion: 31 Dec 2031
Last update posted: 29 Jul 2026
Registered enrollment: 43
Registry id: NCT05024097

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.